Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening
Go back to Acoramidis Demonstrates Real-World Benefit Versus Tafamidis in ATTR-CM, Reducing Risk of Clinical Worsening| (NASDAQ: BBIO) | Delayed: 67.74 +0.19 (0.28%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $67.55 | 52 Week High | $ | |||
| Open | $68.04 | 52 Week Low | $ | |||
| Day High | $68.79 | P/E | N/A | |||
| Day Low | $67.55 | EPS | $ | |||
| Volume | 3,036,099 | |||||



